INOVIO’s first-of-their-kind DNA medicines are precisely designed DNA plasmids delivered through INOVIO’s proprietary smart device — CELLECTRA® — directly into the body’s cells to produce an immune response robust enough to potentially treat or prevent disease.
J. JOSEPH KIM, Ph.D.
PRESIDENT & CHIEF EXECUTIVE OFFICER
“At INOVIO, the revolutionary power of our technology is superseded only by the dedication, passion, and expertise of the team we have brought together to bring our technology to life for patients in need.”
ROBERT J. JUBA JR.
Vice President, Biological Manufacturing and Clinical Supply Management
“INOVIO’s team has extensive experience manufacturing DNA medicines and a proven track record of producing them at unprecedented speeds.”
AMI SHAH BROWN, Ph.D., MPH
Senior Vice President, Regulatory Affairs
“For more than a decade, INOVIO has been working closely with regulators to assess DNA medicines for their potential in disease prevention and treatment, especially for emerging infectious diseases. We are grateful for their guidance and rapid response as we develop our COVID-19 DNA vaccine, in particular as we advance from funding to initiation of our first-in-human trial in ten weeks, a major milestone for INOVIO and our collaborators.”
TIMOTHY HERRING, MPH
“Our team at INOVIO is working tirelessly to not only keep pace with the spread of the virus that causes COVID-19, but also to stay focused on other viruses such as high risk HPV, which is responsible for 70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. We know that patients are waiting.”
PRAKASH BHUYAN, M.D., Ph.D.
Vice President, Clinical Development
“A virus cannot be cut out by a scalpel. DNA medicines represent the first potential non-surgical innovation in the treatment of precancerous cervical, anal, and vulvar dysplasias.”
Senior Vice President, Engineering Development
“INOVIO’s CELLECTRA® intramuscular and intracellular smart devices have allowed us to deliver our optimized DNA plasmids directly into cells in the body to produce immune responses. This delivery has enabled us to overcome a key limitation of other DNA and other nucleic acid approaches, such as mRNA.”
MARK TWYMAN, MBA
Vice President, Commercial
“The goal of our DNA medicines is to redefine success in the treatment of HPV-related diseases, as well as other infectious diseases, and cancers. We are not just talking about incremental improvements.”
SHU PING YANG, Ph.D.
Senior Director, Clinical Development
“INOVIO’s DNA medicines platform may be the best modern approach to addressing potential infectious disease pandemics due to their rapid design and manufacture.”
KATE E. BRODERICK, Ph.D.
Senior Vice President, R&D
“INOVIO is a pioneer in the development of DNA medicines and we won’t rest until we see them achieve their full potential to help people with urgent health needs.”
JACQUELINE SHEA, Ph.D.
CHIEF OPERATING OFFICER
“We are entering a new era in DNA medicines and INOVIO is forging the path by bringing a 21st century approach to both the optimization of DNA plasmids and the delivery of these plasmids through our CELLECTRA® smart device.”
CHIEF FINANCIAL OFFICER
“Our excellent team at INOVIO is driven to realize the potential of DNA medicines to meet urgent health needs associated with HPV-related diseases, cancer, and infectious diseases. We will not rest until we deliver on this potential.”
JEFFREY SKOLNIK, M.D.
VICE PRESIDENT, CLINICAL DEVELOPMENT
“Our goal at INOVIO is to drive the development of DNA medicines as a new way to effectively and safely treat or prevent cancers from destroying lives. We are proud to be at the forefront of this potential game-changing approach to defeating cancer.”
© Copyright 2020 INOVIO Pharmaceuticals. All rights reserved.